Health ❯Healthcare ❯Pharmaceuticals

Weight Loss Drugs

Tirzepatide Zepbound Ozempic GLP-1 Medications Wegovy Semaglutide GLP-1 Therapies GLP-1 Receptor Agonists Eli Lilly Ozempic and Wegovy GLP-1 Class Obesity Treatment Eli Lilly and Novo Nordisk Novo Nordisk GLP-1 Receptor Analogs Medicare and Medicaid Coverage Clinical Trials Eli Lilly vs Novo Nordisk Mounjaro and Zepbound GLP-1 Compounds GLP-1 Drugs Eli Lilly Zepbound Compounded Semaglutide

Novo Nordisk and Eli Lilly Slash Prices for Popular Weight Loss Drugs

Eli Lilly Expands Zepbound Access with New Doses and Lower Prices

FDA Ends Shortage of Tirzepatide, Restricts Compounded Weight-Loss Drugs

FDA Ends Shortage of Eli Lilly’s Weight-Loss Drug, Restricts Copycat Versions

Eli Lilly Partners with Ro to Expand Access to Lower-Cost Zepbound Vials

Dr. Oz Faces Scrutiny Over Conflicts of Interest in Medicare and Medicaid Role

Diabetes and Obesity Drugs Found to Protect Kidney Health

Government Plans Dominate Coverage for Costly Weight-Loss Drugs

New Weight Loss Drug Shows Promise Without Nausea

Limited Access to Popular Weight-Loss Drugs Highlights Socioeconomic Disparities

Supply and Cost Challenges Persist for Popular Weight-Loss Drugs

Cost and Efficacy Concerns Arise for GLP-1 Weight Loss Drugs

Eli Lilly Fights Back Against Compounded Tirzepatide Amid FDA Supply Resolution

Bernie Sanders and Elon Musk Unite on Lowering Ozempic Prices

Eli Lilly Introduces Affordable Zepbound Vials to Address Obesity Drug Shortage

New Study Links Ozempic to Increased Risk of Suicidal Thoughts

Eli Lilly's Tirzepatide Shows 94% Reduction in Diabetes Risk

Compounded Weight Loss Drugs Raise Safety and Ethical Concerns

Eli Lilly's Zepbound Shows Promise in Reducing Heart Failure Risks

Ozempic's Expanding Role: Beyond Diabetes and Weight Loss